Cargando…

Hemostatic Efficacy and Anti-FXa (Factor Xa) Reversal With Andexanet Alfa in Intracranial Hemorrhage: ANNEXA-4 Substudy

Andexanet alfa is a recombinant modified human FXa (factor Xa) developed to reverse FXa inhibition from anticoagulants. Hemostatic efficacy and reversal of anti-FXa activity with andexanet were assessed in patients from the ANNEXA-4 study (Andexanet Alfa, a Novel Antidote to the Anticoagulation Effe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Demchuk, Andrew M., Yue, Patrick, Zotova, Elena, Nakamya, Juliet, Xu, Lizhen, Milling, Truman J., Ohara, Tomoyuki, Goldstein, Joshua N., Middeldorp, Saskia, Verhamme, Peter, Lopez-Sendon, Jose Luis, Conley, Pamela B., Curnutte, John T., Eikelboom, John W., Crowther, Mark, Connolly, Stuart J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2021
Materias:	Original Contributions
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8140631/ https://www.ncbi.nlm.nih.gov/pubmed/33966491 http://dx.doi.org/10.1161/STROKEAHA.120.030565

Ejemplares similares

Andexanet Alfa for Specific Anticoagulation Reversal in Patients with Acute Bleeding during Treatment with Edoxaban
por: Benz, Alexander P., et al.
Publicado: (2022)

Andexanet versus prothrombin complex concentrates: Differences in reversal of factor Xa inhibitors in in vitro thrombin generation
por: Lu, Genmin, et al.
Publicado: (2020)

Restart of Anticoagulant Therapy and Risk of Thrombosis, Rebleeding, and Death after Factor Xa Inhibitor Reversal in Major Bleeding Patients
por: Milling, Truman J., et al.
Publicado: (2021)

Measuring residual anti‐Xa activity of direct factor Xa inhibitors after reversal with andexanet alfa
por: Bourdin, Matthieu, et al.
Publicado: (2021)

Exhibition of Uterus and Annexa
por: Croom, Halliday
Publicado: (1879)

Coagulation Factor Xa (Recombinant), Inactivated-Zhzo (Andexanet Alfa) Hemostatic Outcomes and Thrombotic Event Incidence at an Academic Medical Center
por: Stevens, Victoria M., et al.
Publicado: (2019)

Reversing factor Xa inhibitors – clinical utility of andexanet alfa
por: Kaatz, Scott, et al.
Publicado: (2017)

Andexanet alfa for reversal of factor Xa inhibitor-associated anticoagulation
por: Carpenter, Elise, et al.
Publicado: (2019)

Evaluation of oral factor Xa inhibitor‐associated extracranial bleeding reversal with andexanet alfa
por: Nederpelt, Charlie J., et al.
Publicado: (2020)

Andexanet Alfa for Reversal of Factor Xa Inhibitors in Intracranial Hemorrhage: Observational Cohort Study
por: Rauch, Sebastian, et al.
Publicado: (2022)

Preclinical and clinical data for factor Xa and “universal” reversal agents(,,)
por: Milling, Truman J., et al.
Publicado: (2016)

Preclinical and Clinical Data for Factor Xa and “Universal” Reversal Agents
por: Milling, Truman J., et al.
Publicado: (2016)

Ichthyol as a Therapeutic Agent in the Treatment of Diseases of the Uterine Annexa
por: Bell, Robert
Publicado: (1896)

Reversal of Factor Xa Inhibitors by Andexanet Alfa May Increase Thrombogenesis Compared to Pretreatment Values
por: Siddiqui, Fakiha, et al.
Publicado: (2019)

Andexanet alfa effectively reverses edoxaban anticoagulation effects and associated bleeding in a rabbit acute hemorrhage model
por: Lu, Genmin, et al.
Publicado: (2018)

Re-initiation of dabigatran and direct factor Xa antagonists after a major bleed(,,)
por: Milling, Truman J., et al.
Publicado: (2016)

Re-Initiation of Dabigatran and Direct Factor Xa Antagonists After a Major Bleed
por: Milling, Truman J., et al.
Publicado: (2016)

Retrospective Comparison of Andexanet Alfa and 4-Factor Prothrombin Complex for Reversal of Factor Xa-Inhibitor Related Bleeding
por: Stevens, Victoria M., et al.
Publicado: (2021)

Efficacy and Safety of Andexanet Alfa for Bleeding Caused by Factor Xa Inhibitors: A Systematic Review and Meta-Analysis
por: Shrestha, Dhan B, et al.
Publicado: (2021)

A meta‐analysis of andexanet alfa and prothrombin complex concentrate in the treatment of factor Xa inhibitor–related major bleeding
por: Jaspers, Tessa, et al.
Publicado: (2021)

In vitro reversal of direct factor Xa inhibitors: Direct comparison of andexanet alfa and prothrombin complex concentrates Cofact and Beriplex/Kcentra
por: Brinkman, Herm Jan M., et al.
Publicado: (2022)

Treatment of Factor-Xa Inhibitor-associated Bleeding with Andexanet Alfa or 4 Factor PCC: A Multicenter Feasibility Retrospective Study
por: Singer, Adam J., et al.
Publicado: (2023)

Thirty‐day mortality with andexanet alfa compared with prothrombin complex concentrate therapy for life‐threatening direct oral anticoagulant‐related bleeding
por: Cohen, Alexander T., et al.
Publicado: (2022)

Use of a Genetic Variant Related to Circulating FXa (Activated Factor X) Levels to Proxy the Effect of FXa Inhibition on Cardiovascular Outcomes
por: Gill, Dipender, et al.
Publicado: (2020)

Andexanet Alfa: First Global Approval
por: Heo, Young-A
Publicado: (2018)

Institutional Experience of Using Andexanet Alfa
por: Khadka, Sushmita, et al.
Publicado: (2020)

Synthesis and evaluation of anthranilamide-based derivatives as FXa inhibitors
por: Huang, Changjiang, et al.
Publicado: (2017)

Thromboprophylaxis in COVID-19: Anti-FXa—the Missing Factor?
por: Dutt, Tina, et al.
Publicado: (2020)

Correction to: Andexanet Alfa: First Global Approval
por: Heo, Young-A
Publicado: (2018)

Anti-FXa Activity with Intermediate-Dose Thromboprophylaxis in COVID-19
por: Rappaport, Stephen H., et al.
Publicado: (2020)

Real-world clinical outcomes among US Veterans with oral factor xa inhibitor–related major bleeding treated with andexanet alfa or 4-factor prothrombin complex concentrate
por: Sutton, S. Scott, et al.
Publicado: (2023)

Lower mortality with andexanet alfa vs 4-factor prothrombin complex concentrate for factor Xa inhibitor-related major bleeding in a U.S. hospital-based observational study
por: Dobesh, Paul P., et al.
Publicado: (2023)

Innovative Three-Step Microwave-Promoted Synthesis of N-Propargyltetrahydroquinoline and 1,2,3-Triazole Derivatives as a Potential Factor Xa (FXa) Inhibitors: Drug Design, Synthesis, and Biological Evaluation
por: Santana-Romo, Fabián, et al.
Publicado: (2020)

Apixaban-Calibrated Anti-FXa Activity in Relation to Outcome Events and Clinical Characteristics in Patients with Atrial Fibrillation: Results from the AVERROES Trial
por: Bhagirath, Vinai C., et al.
Publicado: (2017)

Correction to: Real-world clinical outcomes among US Veterans with oral factor xa inhibitor-related major bleeding treated with andexanet alfa or 4-factor prothrombin complex concentrate
por: Sutton, S. Scott, et al.
Publicado: (2023)

In silico Discovery of Novel FXa Inhibitors by Pharmacophore Modeling and Molecular Docking
por: Pu, Yinglan, et al.
Publicado: (2017)

Difficult Intraoperative Heparinization Following Andexanet Alfa Administration
por: Watson, C. James, et al.
Publicado: (2019)

Differential Neutralization of Unfractionated Heparin and Enoxaparin by Andexanet Alfa
por: Lewis, Joseph, et al.
Publicado: (2022)

Successful use of an antithrombin for heparin resistance with andexanet alfa
por: Honda, Jun, et al.
Publicado: (2023)

Novel Anthranilamide-Based FXa Inhibitors: Drug Design, Synthesis and Biological Evaluation
por: Wang, Wenzhi, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ohpnqmiekplid1j7aieb6s8veo